Guido Finazzi
#158,153
Most Influential Person Now
Guido Finazzi's AcademicInfluence.com Rankings
Guido Finazziphilosophy Degrees
Philosophy
#9006
World Rank
#12496
Historical Rank
Logic
#6014
World Rank
#7489
Historical Rank

Download Badge
Philosophy
Guido Finazzi's Degrees
- PhD Biomedical Sciences University of Milan
- Doctorate Medicine University of Milan
Why Is Guido Finazzi Influential?
(Suggest an Edit or Addition)Guido Finazzi's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. (2007) (893)
- Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. (1995) (790)
- Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. (2011) (745)
- Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. (2005) (633)
- Cardiovascular events and intensity of treatment in polycythemia vera. (2013) (621)
- Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. (2014) (552)
- The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. (1997) (528)
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study (2013) (506)
- Inherited thrombophilia: pathogenesis, clinical syndromes, and management. (1996) (474)
- A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) 1 (2005) (457)
- Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. (2007) (454)
- Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. (1990) (448)
- Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. (1996) (444)
- Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). (2012) (424)
- Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. (2005) (403)
- Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. (2007) (366)
- Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. (2011) (365)
- Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet (2018) (342)
- Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments (2008) (325)
- Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. (2007) (306)
- Myeloproliferative neoplasms and thrombosis. (2013) (303)
- A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms (2010) (235)
- High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. (1991) (228)
- Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. (2009) (227)
- Thrombosis in primary myelofibrosis: incidence and risk factors. (2009) (213)
- Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long‐term follow‐up of a randomized clinical trial (2000) (209)
- Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. (2013) (200)
- Defibrotide for the treatment of hepatic veno‐occlusive disease: results of the European compassionate‐use study (2000) (195)
- Leukocytosis and risk stratification assessment in essential thrombocythemia. (2007) (192)
- The haematocrit and platelet target in polycythemia vera (2007) (186)
- Thrombotic and Hemorrhagic Complications in Patients with Mechanical Heart Valve Prosthesis Attending an Anticoagulation Clinic (1993) (173)
- Different Prevalence of Thromboembolism in the Subtypes of Congenital Antithrombin III Deficiency:Review of 404 Cases (1987) (172)
- Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). (2011) (170)
- Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera (2000) (169)
- Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. (2007) (167)
- Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. (1995) (165)
- Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia (2015) (165)
- Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3 (2011) (162)
- Clinical Manifestations and Management of Inherited Thrombophilia: Retrospective Analysis and Follow-up after Diagnosis of 238 Patients with Congenital Deficiency of Antithrombin III, Protein C, Protein S (1994) (161)
- Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? (2009) (150)
- Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. (1999) (150)
- Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. (1984) (148)
- Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. (2011) (148)
- The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. (2006) (145)
- Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. (2007) (145)
- A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process (2010) (143)
- Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria (2012) (139)
- How I treat patients with polycythemia vera. (2007) (131)
- The Impact of All-trans-Retinoic Acid on the Coagulopathy of Acute Promyelocytic Leukemia (1998) (123)
- Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. (2000) (120)
- The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. (1998) (119)
- A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy (2013) (118)
- Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. (2008) (115)
- Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. (2008) (110)
- Hydroxyurea‐related toxicity in 3,411 patients with Ph'‐negative MPN (2012) (109)
- Chronic myeloproliferative disorders. (2003) (107)
- Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. (2005) (105)
- A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group (2007) (104)
- Evidence and expertise in the management of polycythemia vera and essential thrombocythemia (2008) (104)
- In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. (2014) (103)
- The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. (2016) (98)
- Markers of Procoagulant Imbalance in Patients with Inherited Thrombophilic Syndromes (1992) (98)
- JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. (2009) (97)
- Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. (2012) (89)
- The Italian Registry of Antiphospholipid Antibodies. (1997) (81)
- A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment. (2000) (79)
- Antiphospholipid antibodies in early repeated abortions: a case-controlled study. (1988) (78)
- Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment (2009) (78)
- Thrombosis in Cancer Patients Treated with Hematopoietic Growth Factors - A Meta-Analysis (1996) (76)
- Risk-adapted therapy in essential thrombocythemia and polycythemia vera. (2005) (75)
- White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. (2015) (75)
- When and how to treat essential thrombocythemia. (2005) (74)
- Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. (2014) (72)
- Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature. (1997) (72)
- Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). (1999) (72)
- Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients (2016) (71)
- Coinheritance of the HR2 Haplotype in the Factor V Gene Confers an Increased Risk of Venous Thromboembolism to Carriers of Factor V R506Q (Factor V Leiden) (1999) (71)
- Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults (1991) (69)
- The Risk of Thrombosis in Patients with Lupus Anticoagulants Is Predicted by their Specific Coagulation Profile (1999) (67)
- A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). (2004) (66)
- Thrombocytopenia in the antiphospholipid syndrome (1996) (66)
- Diagnosis and Treatment of Polycythemia Vera and Possible Future Study Designs of the PVSG (2000) (66)
- Different Incidence of Venous Thrombosis in Patients with Inherited Deficiencies of Antithrombin III, Protein C and Protein S (1994) (65)
- Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. (2012) (64)
- Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. (1999) (64)
- Masked polycythemia vera diagnosed according to WHO and BCSH classification (2014) (64)
- Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry. Italian Registry of Antiphospholipid Antibodies (IR-APA). (1993) (64)
- Clinical parameters for determining when and when not to treat essential thrombocythemia. (1999) (64)
- Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. (2010) (63)
- Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. (2003) (63)
- High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists (2016) (63)
- Diagnosis of essential thrombocythemia at platelet counts between 400 and 600x10(9)/L. Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC). (2000) (59)
- The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. (2005) (59)
- JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. (2011) (58)
- Masked polycythemia Vera (mPV): Results of an international study (2013) (58)
- Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia (2009) (57)
- Masked polycythemia Vera (mPV): Results of an international study (2014) (56)
- Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening (1993) (55)
- Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. (1996) (54)
- Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study (2019) (54)
- Diagnosis of Mycobacterium bovis infection in calves sensitized by mycobacteria of the avium/intracellulare group. (2002) (52)
- Myeloproliferative disease in pregnancy and other management issues. (2006) (52)
- Leukocytosis as an important risk factor for arterial thrombosis in WHO‐defined early/prefibrotic myelofibrosis: An international study of 264 patients (2012) (51)
- A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group (2007) (51)
- Phospholipid‐dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia (2014) (51)
- Antiphospholipid Antibodies: Predictive Value of Laboratory Tests (1997) (51)
- Treatment of polycythemia vera. (1998) (50)
- Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis (2013) (50)
- The G1691 → A mutation of factor V, but not the G20210 → A mutation of factor II or the C677 → T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants (2000) (50)
- Pregnancy complications predict thrombotic events in young women with essential thrombocythemia (2014) (50)
- The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera (2011) (49)
- HEREDITARY DYSFUNCTIONAL PROTEIN C (PROTEIN C BERGAMO) AND THROMBOSIS (1984) (47)
- Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes. (1996) (47)
- Cutaneous manifestations associated with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome: a case-control study. (1993) (47)
- Front-line therapy in polycythemia vera and essential thrombocythemia. (2012) (47)
- Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases (2018) (47)
- A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera (2014) (46)
- A reappraisal of the benefit‐risk profile of hydroxyurea in polycythemia vera: A propensity‐matched study (2017) (46)
- Sale of raw milk in northern Italy: food safety implications and comparison of different analytical methodologies for detection of foodborne pathogens. (2012) (44)
- The effect of arterial hypertension on thrombosis in low‐risk polycythemia vera (2017) (44)
- Antithrombin Vicenza, Ala 384 to Pro (GCA to CCA) mutation, transforming the inhibitor into a substrate (1991) (44)
- Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) (2014) (43)
- Treatment of essential thrombocythemia with special emphasis on leukemogenic risk (1999) (42)
- Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation (2010) (42)
- Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms (2017) (40)
- The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells. (2012) (40)
- Recurrence after first cerebral infarction in young adults (2000) (40)
- Foodborne pathogens in in-line milk filters and associated on-farm risk factors in dairy farms authorized to produce and sell raw milk in northern Italy. (2012) (39)
- ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. (2013) (37)
- Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018 (2018) (36)
- L-Asparaginase Lowers Protein C Antigen (1984) (35)
- PATIENTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA (2013) (34)
- Quantitative risk assessment of verocytotoxin-producing Escherichia coli O157 and Campylobacter jejuni related to consumption of raw milk in a province in Northern Italy. (2012) (34)
- Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms (2018) (33)
- Inefficacy of intravenous immunoglobulin in patients with low‐risk thrombotic thrombocytopenic purpura/hemolytic‐uremic syndrome (1992) (33)
- Prefibrotic myelofibrosis: treatment algorithm 2018 (2018) (32)
- Interaction between platelets and lupus anticoagulant (1988) (31)
- Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients. (2013) (30)
- Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results (2012) (30)
- Thrombocytopenia in the antiphospholipid syndrome: pathophysiology, clinical relevance and treatment. (1996) (30)
- A frameshift mutation leading to type 1 antithrombin deficiency and thrombosis. (1990) (29)
- How to manage essential thrombocythemia (2012) (28)
- Risk factors and prevention of vascular complications in polycythemia vera. (1997) (28)
- Maternal Lupus Anticoagulant and Fatal Neonatal Thrombosis (1987) (28)
- CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis (2014) (27)
- Low incidence of bleeding from HIV‐related thrombocytopenia in drug addicts and hemophiliacs: Implications for therapeutic strategies (1990) (27)
- Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: "Pros" and "Cons". (2012) (27)
- Idiopathic erythrocytosis and other non-clonal polycythemias. (2006) (27)
- EPIDEMIOLOGICAL, DIAGNOSTIC, THERAPEUTIC AND PROGNOSTIC ASPECTS OF ESSENTIAL THROMBOCYTHEMIA IN RETROSPECTIVE STUDY OF THE GIMMC GROUP IN TWO THOUSAND PATIENTS (1997) (26)
- Immunoelectrophoretic evidence of a thrombin‐induced abnormality in a new variant of hereditary dysfunctional antithrombin III (AT III ‘Vicenza’) (1983) (25)
- The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting (2018) (25)
- Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia (2012) (24)
- Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post‐ASH symposium (2012) (24)
- ASXL1 mutations in primary and secondary myelofibrosis (2012) (23)
- Survival of Arcobacter butzleri during production and storage of artisan water buffalo mozzarella cheese. (2013) (23)
- Second cancers in MPN: Survival analysis from an international study (2019) (23)
- Antiphospholipid syndrome associated with immunotherapy for patients with melanoma (1995) (22)
- Evidence-based management of polycythemia vera. (2006) (22)
- Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis (2019) (22)
- Are MPNs Vascular Diseases? (2013) (22)
- Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms (2018) (22)
- Glucose‐6‐phosphate dehydrogenase deficiency: genetic heterogeneity in Sardinia (1982) (22)
- Clinical Trials on Antiphospholipid Syndrome: What is Being Done and What is Needed? (1994) (22)
- Apparent Heterozygous Type II Protein C Deficiency Caused by the Factor V 506 Arg to GIn Mutation (1995) (21)
- Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. (2007) (20)
- Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper (2019) (20)
- A guide to oral anticoagulant therapy (1998) (19)
- Fibrinogen Bergamo I (Aα16Arg → Cys): Susceptibility Towards Thrombin Following Aminoethylation, Methylation or Carboxamidomethylation of Cysteine Residues (1985) (19)
- A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results (2010) (19)
- Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations. (2019) (19)
- Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO‐criteria and stratified by calendar period of diagnosis (2015) (18)
- Clinical Coagulation Laboratory and Oral Anticoagulant Therapy Treatment. Instrumentation and Methodology (1995) (18)
- The treatment of polycythaemia vera: an update in the JAK2 era (2007) (18)
- Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study (2011) (17)
- Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer. A case-control study. (2019) (17)
- A common point mutation producing type 1A antithrombin III deficiency: AT129 CGA to TGA (Arg to Stop). (1991) (17)
- Efficacy and safety of hydroxyurea in patients with essential thrombocythemia. (2001) (17)
- Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium (2011) (17)
- Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera (2018) (17)
- Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia. (2003) (16)
- Antiphospholipid antibodies and necrotizing purpura. (1990) (16)
- Immunohistologic Diagnosis of Pseudorabies (Aujeszky's Disease) using Monoclonal Antibodies (1997) (16)
- A guide to oral anticoagulant treatment. Recommendations of the Italian federation of anticoagulation clinics (FCSA) (2003) (16)
- The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts (2017) (15)
- Heparin-induced thrombocytopenia--background and implications for haemodialysis. (1996) (15)
- Coinheritance of the HR 2 Haplotype in the Factor V Gene Confers an Increased Risk of Venous Thromboembolism to Carriers of Factor V R 506 Q ( Factor V Leiden ) (1999) (15)
- How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey (2020) (15)
- COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey (2020) (15)
- Rituximab in autoimmune cytopenias: for which patients? (2002) (14)
- A guide to oral anticoagulant treatment (1998) (14)
- The epidemiology of the antiphospholipid syndrome: Who is at risk? (2001) (14)
- Primary antithrombotic prevention in carriers of antiphospholipid antibodies without systemic autoimmune disorders (2012) (13)
- INTRAVENOUS GAMMAGLOBULIN, ANTIPHOSPHOLIPID ANTIBODIES, AND THROMBOCYTOPENIA (1988) (13)
- Feasibility of a randomized clinical trial for the prevention of recurrent thrombosis in the antiphospholipid syndrome: the WAPS project. Provisional Steering Committee of the Warfarin in Antiphospholipid Syndrome (WAPS) Study. (1996) (13)
- Special Issues in Myeloproliferative Neoplasms (2011) (13)
- Oral anticoagulant therapy in hemodialysis patients: do the benefits outweigh the risks? (2009) (13)
- Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? No (2008) (13)
- A Phase II Study of the HDAC Inhibitor Givinostat In Combination with Hydroxyurea In Patients with Polycythemia Vera Resistant to Hydroxyurea Monotherapy (2011) (13)
- A survey study on safety and microbial quality of “gluten-free” products made in Italian pasta factories (2017) (13)
- Congenital Resistance to Activated Protein C in Patients with Lupus Anticoagulants: Evaluation of Two Functional Assays (1998) (11)
- Antiblastic therapy and thrombosis (1992) (10)
- Seasonal Variability of Thermophilic Campylobacter Spp. in Raw Milk Sold by Automatic Vending Machines in Lombardy Region (2016) (10)
- Bleeding and thrombosis in acute lymphoblastic leukemia. (1993) (10)
- Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. (2011) (9)
- Behaviour of Salmonella Typhimurium during production and storage of artisan water buffalo Mozzarella cheese (2012) (9)
- Direct oral anticoagulants in rare venous thrombosis (2016) (9)
- Ruxolitinib in ET: not all MPN are equal. (2017) (9)
- Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era? (2015) (9)
- Preparation of Powdered Infant Formula: Could Product's Safety Be Improved? (2018) (9)
- MULTIPLE MYELOME IN A PAIR OF TWINS (1987) (9)
- Behaviour of Listeria monocytogenes in packaged water buffalo mozzarella cheese (2011) (9)
- Purification of antithrombin ‘Vicenza’: a molecule with normal heparin affinity and impaired reactivity to thrombin (1985) (8)
- PO-26 - Whole blood rotational thromboelastometry (ROTEM) to detect hypercoagulability in patients with myeloproliferative neoplasms (MPN). (2016) (8)
- Etretinate therapy and thrombocytopenia (1991) (8)
- Essential thrombocythemia. (2008) (8)
- Essential thrombocythemia. (2005) (7)
- Clinical trials in myeloproliferative disorders: looking forward. (2005) (7)
- Recurrent thrombosis in patients with polycythemia vera or essential thrombocythemia : efficacy of treatment in preventing rethrombosis in different clinical settings (2006) (7)
- Management of essential thrombocythemia. (1999) (7)
- Molecular characterisation and biofilm production in Staphylococcusaureus isolates from the dairy production chain in Northern Italy (2019) (7)
- A Two-Part Study of Givinostat in Patients with Polycythemia Vera: Maximum Tolerated Dose Definition and Preliminary Efficacy Results (2016) (7)
- Expertise-Based Management in Essential Thrombocythemia and Polycythemia Vera (2007) (7)
- Risk of Venous Thromboembolism and Clinical Manifestations in Carriers of Antithrombin , Protein C , Protein S Deficiency , or Activated Protein C Resistance (1999) (7)
- Prophylactic platelet transfusion in acute leukemia: which threshold should be used. (1998) (6)
- Study of Growth Potential of Listeria Monocytogenes in Low Fat Salami: An Innovative Italian Meat Product (2014) (6)
- Antiphospholipid antibodies and melanoma: a link? (1992) (6)
- The management of ‘low‐risk’ and ‘intermediate‐risk’ patients with primary thrombocythaemia (1999) (6)
- IgM gammopathy and the lupus anticoagulant syndrome in habitual aborters. (1986) (6)
- Two novel (R(−11)C; T394D) and two repeat missense mutations in the protein C gene associated with venous thrombosis in six kindreds (1996) (5)
- Contamination of Poultry Meat with Salmonella infantis should be considered a Risk for Food Safety? (2019) (5)
- Leukocytosis as an Independent Risk Factor for Thrombosis in Polycythemia Vera. (2006) (5)
- Low Prevalence of JAK2 Val617Phe Mutation in Patients with Idiopathic Erythrocytosis. (2005) (5)
- Risk stratification, staging, and treatment of patients with polycythemia vera: Italian and European collaboration on low-dose aspirin in polycythemia data. (2006) (5)
- Self-testing and self-monitoring of oral anticoagulant therapy: consensus of the Italian Federation of Anticoagulation Clinics (2003) (5)
- A retrospective study on oral anticoagulant prophylaxis in 103 Italian patients with hereditary thrombophilia and thrombosis (1990) (5)
- Two unlinked cases of foodborne botulism in Italy at the beginning of 2010. (2011) (4)
- Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm (2015) (4)
- Antiphospholipid Antibodies and Associated Clinical Manifestations. (1996) (4)
- FLOQSwab™: Optimisation of Procedures for the Recovery of Microbiological Samples from Surfaces (2016) (4)
- Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin (2019) (4)
- Investigation and Follow-Up of a Staphylococcal Food Poisoning Outbreak Linked to the Consumption of Traditional Hand-Crafted Alm Cheese (2020) (4)
- A Structural Study on the Listeria Monocytogenes Internalin A—Human E-cadherin Interaction: A Molecular Tool to Investigate the Effects of Missense Mutations (2020) (4)
- How Epidemiology of Polycythemia Vera Has Changed in the Last 10 Years: Results From the Whole Prospective Cohort of Patients in Cyto-PV Trial As Compared with Eclap Prospective Cohort (2012) (4)
- European leukemianet-integration of the leading national leukemia networks (CML, AML, ALL, CLL, MDS, CMPD) another interdisciplinary partner groups in Europe (2007) (4)
- Silter Cheese, a Traditional Italian Dairy Product: A Source of Feasible Probiotic Strains (2015) (4)
- Multiple myeloma in a pair of twins. (1987) (4)
- [Antiphospholipid antibody syndrome]. (1999) (3)
- The HDAC INHIBITOR ITF2357 MODULATES KEY HEMATOPOIETIC GENES in JAK2V617F CELLS From MYELOPROLIFERATIVE Neoplasm PATIENTS (2010) (3)
- Chronic myeloid disorders, excluding CML (2004) (3)
- Abnormal leukocyte scattergrams and immature platelet fraction on Sysmex XN-9000 analyzer: a new diagnostic tool for altered megakaryopoiesis? (2017) (3)
- Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative (2019) (3)
- A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results (2013) (3)
- Recombinant Versus High-sensitivity Conventional Thromboplastin: A Randomized Clinical Study in Patients on Oral Anticoagulation (1994) (3)
- Infant Botulism: Checklist for Timely Clinical Diagnosis and New Possible Risk Factors Originated from a Case Report and Literature Review (2021) (3)
- [Clinical significance and predictive value of laboratory tests in thrombosis associated with antiphospolipid antibodies]. (1997) (3)
- Two novel (R(-11)C; T394D) and two repeat missense mutations in the protein C gene associated with venous thrombosis in six kindreds. (1996) (3)
- Essential thrombocytemia and ischemic stroke: Report of six cases (1994) (3)
- Determinants of thrombin generation in gynaecological malignancies (2016) (2)
- Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms (2018) (2)
- The Management of Essential Thrombocythaemia. (1997) (2)
- Increased Platelet Thrombus Formation Under Flow Condition In Myeloproliferative Neoplasms (MPN) (2013) (2)
- Thrombotic and Hemorrhagic Complications after Surgery in Patients with Essential Thrombocythemia and Polycythemia Vera. (2006) (2)
- DYNAMICS OF LISTERIA MONOCYTOGENES, SALMONELLA TYPHIMURIUM ESCHERICHIA COLI O157: H7 DURING THE PRODUCTION OF ‘NDUJA (2011) (2)
- Givinostat for the treatment of polycythemia vera (2014) (2)
- A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group (2014) (2)
- Platelet Adhesion Under Flow Condition in Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV): Analysis According to the Mutational Status (2015) (2)
- Hereditary dysfunctional protein C (protein C "Bergamo II") diagnosed by a rapid assay. (1987) (2)
- A Large-Scale Trial Testing the Intensity of Cytoreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera (CYTO-PV trial) (2012) (2)
- Molecular basis of protein C deficiency in five patients with thrombophilia. (1993) (2)
- Association between lupus anticoagulant and epilepsy (1987) (1)
- [Clinical research at the European LeukemiaNet]. (2006) (1)
- A Listeria monocytogenes ST325 clone is widespread in the Lombardy Region dairy processing plants (2020) (1)
- Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study. (2012) (1)
- Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms (2018) (1)
- Management of special conditions in patients on vitamin K antagonists (2012) (1)
- Platelets in Thrombotic and Non-thrombotic Disorders: Thrombocytosis and thrombocythemia (2002) (1)
- Microparticle-Associated Thrombin Generation and Procoagulant Activity Is Increased In Patients with Essential Thrombocythemia (2010) (1)
- Ongoing randomized clinical trials for the treatment of thrombosis in the antiphospholipid syndrome (2001) (1)
- Is SARS-CoV-2 a Concern for Food Safety? A Very Low Prevalence from a Food Survey during the COVID-19 Pandemic in Northern Italy (2022) (1)
- Prefibrotic myelofibrosis: treatment algorithm 2018 (2018) (1)
- Short and Long-Term Risk of Major Cardiovascular Events after Ischemic Stroke or Transient Ischemic Attack in Myeloproliferative Neoplasms (2017) (1)
- PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status. (2016) (1)
- Foodborne botulism survey in Northern Italy from 2013 to 2020: Emerging risk or stable situation? (2022) (1)
- Neurosarcoidosis, stroke and antiphospholipid antibodies: a case report (1996) (1)
- Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls (2019) (1)
- ADP-Induced Whole Blood Aggregometry and Platelet-Associated Thrombin Generation (TG) In Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Patients (2010) (1)
- Contents, Vol. 180, 1990 (1990) (0)
- Intrinsic and method-induced variation of the bleeding time and related parameters (2007) (0)
- Listeria monocytogenes behaviour in gastronomy food: rice salad. (2010) (0)
- Dynamic of several pathogens in artificially contaminated Salame Piacentino DOP. (2009) (0)
- Unanswered questions in polycythaemia vera (2007) (0)
- Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms (2018) (0)
- Antiphospholipid antibodies and intravascular thrombosis. (1994) (0)
- expert panel primary myelofibrosis: recommendations from an ad hoc international diagnostic criteria for polycythemia vera, essential thrombocythemia, and Proposals and rationale for revision of the World Health Organization (2013) (0)
- High-Sensitivity C-Reactive Protein (hs-CRP) and Pentraxin 3 (PTX3) Are Increased in Essential Thrombocythemia and Polycythemia Vera. (2009) (0)
- Shelf-life assessment of Modena DOP raw ham sold in vacuum packed pieces. (2010) (0)
- STEC prevalence in raw milk cheese produced in LombardiaBarbara Bertasi (2016) (0)
- polycythemia vera or essential thrombocythemia Clinical profile of homozygous JAK2 617V>F mutation in patients with (2013) (0)
- ESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV) PATIENTS SHOW AN INCREASED THROMBUS FORMATION IN A DYNAMIC MODEL OF PLATELET ADHESION (2017) (0)
- Gluten quantification in gluten-free food for celiac people in Lombardy and Emilia Romagna - Italy (2022) (0)
- PREVALENCE OF A N T I T H R O M B I N III DEFICIENCY IN BLOOD DONORS SELECTED FOR PERSONAL OR FAMILIAL HISTORY OF VENOUS THROMBOSIS (0)
- Management of Patients with Essential Thrombocythemia (2009) (0)
- OCCURRENCE OF LISTERIA MONOCYTOGENES IN READY TO EAT FOOD SAMPLES COLLECTED BY LOMBARDY REGION HEALTH AUTHORITIES IN 2009-2010 (2012) (0)
- Cerebral ischemia in a patient with protein S deficiency and carotid stenosis (1994) (0)
- Abnormal reactivity with thrombin of a new variant of dysfunctional antithrombin (AT ‘Vicenza’) (1984) (0)
- (IPSET-thrombosis) essential thrombocythemia - thrombosis in World Health Organization Development and validation of an International Prognostic Score of (2013) (0)
- Botulinum toxin inactivation during cooking of artificially contaminated potato gnocchi. (2009) (0)
- Similar Rate of Thrombosis in Essential Thrombocythemia and Polycythemia Vera Patients after Stratification for JAK2 V617F Allele Burden. (2008) (0)
- essential thrombocythemia, polycythemia vera, and myelofibrosis Long-term survival and blast transformation in molecularly annotated (2014) (0)
- PO-52 Determination of thrombin generation (TG) and procoagulant activity (PCA) expressed by circulating microparticles (MP) in essential thrombocythemia (ET) patients (2010) (0)
- Response: Thrombocytosis in low-risk ET patients (2008) (0)
- [Management of quantitative and qualitative platelet defects]. (1999) (0)
- PB2192 GLOBAL COAGULATION CAPACITY OF ESSENTIAL THROMBOCYTHEMIA PATIENTS BY ROTEM ANALYSIS ADJUSTED FOR PLATELET COUNT CORRELATES WITH THROMBOTIC RISK CLASS (2019) (0)
- Newly Designed Primers for the Sequencing of the inlA Gene of Lineage I and II Listeria monocytogenes Isolates (2022) (0)
- Leucocytosis is a risk factor for recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia (2009) (0)
- Potent Inhibition of EEC Colony Formation in JAK2V617F PV and ET by Low Doses of ITF2357, a New Histone Deacetylase Inhibitor. (2006) (0)
- A frameshift mutation in the antithrombin gene leading to type 1 deficiency and thrombosis (1990) (0)
- Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms (2018) (0)
- Thrombophilia as a polygenic disease: A study of 24 genetically characterized protein C deficient probands with thrombosis (1999) (0)
- Monitoring of Vibrio spp. in edible molluscs, lamellibranchia and sea water [Conference poster]. (2012) (0)
- Polycythaemia vera (2020) (0)
- Successful treatment with heparin of cerebral vein thrombosis in young patients (1992) (0)
- Quantifying LAB populations in raw milk and dairy products through a Real Time PCR assay (2018) (0)
- Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018 (2018) (0)
- Intestato parente mortuo adgnatis defertur tutela: sul principio d'identità fra eredità e tutela. (2016) (0)
- JAK2V617F Mutation and Thrombosis History Are Determinants of Mean Platelet Volume (MPV) in Essential Thrombocythemia Patients (2016) (0)
- Dynamics of several pathogen microorganisms in packaged water-buffalo mozzarella cheese. (2010) (0)
- Behavioural dynamics of several pathogen microorganisms during processing and ripening of Bagòss cheese. (2009) (0)
- The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting (2018) (0)
- Mycobacterium bovis experimental infection in three calves (1999) (0)
- Biofilm formation by different genotypes of dairy Staphylococcus aureus isolates from Northern Italy (2018) (0)
- Current Treatment Approaches of Polycythemia Vera (2006) (0)
- Risk Factors for Thrombosis in WHO-Defined Early/Prefibrotic Myelofibrosis: An International Study of 264 Patients, (2011) (0)
- Predicting the survival of Salmonella spp. in Italian salami [Calabria; Lombardy] (2005) (0)
- Diagnosis of human botulism in Northern Italy during 2012-2016Guido Finazzi (2017) (0)
- Sensitivity and Specificity of Laboratory Parameters to Detect Early/Prefibrotic Myelofibrosis in 857 Patients with Essential Thrombocythemia. A Diagnostic Algorithm (2011) (0)
- Integrated veterinary-medical activity on characterization of shigatoxin producing Escherichia coli (2019) (0)
- The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase (JAK) inhibitor: A phase 2, randomized study. (2016) (0)
- Hydroxyurea: the comparator in studies with new anti-JAK2 inhibitors (2009) (0)
- Recurrent Venous Thrombosis in Patients with Polycythemia Vera and Essential Thrombocythemia (2007) (0)
- Therapy of Polycythemia Vera and Essential Thrombocythemia (2011) (0)
- Prevalence of antithrombin III deficiency in blood donors selected for personal or familial history of venous thrombosis (1985) (0)
- WAPS (warfarin in the antiphospholipid syndrome) study Clinical significance of different antiphospholipid antibodies in the (2013) (0)
- Foodborne outbreak of gastroenteritis caused by Staphyilococcal enterotoxin in Northern Italy (2018) (0)
- Clotting system activation in patients with cancer undergoing major surgery: The role of heparin prophylaxis (1992) (0)
- Pregnancies in Patients with Philadelphia Negative Chronic Myeloproliferative Disorders: Interim Report of the European LeukemiaNet Data Base (2008) (0)
- Rebuttal to the Letter to the Editor by Dr. A. Girolami (1993) (0)
- POINT MUTATIONS PRODUCING TYPE-1A ANTITHROMBIN-III DEFICIENCY (1991) (0)
- The newly diagnosed patient with essential thrombocythemia (2016) (0)
- thrombocythemia: a retrospective survey Post-surgery outcomes in patients with polycythemia vera and essential (2013) (0)
- PS1468 IMPACT OF CYTOREDUCTIVE DRUGS ON SECOND CANCER IN MYELOPROLIFERATIVE NEOPLASMS (2019) (0)
- JAK2 Val617Phe Mutation Correlates with the Risk of Thrombosis in Patients with Essential Thrombocythemia. (2005) (0)
- Preclinical Advances in the Pathogenesis and Therapy of Myeloproliferative Neoplasms TET 2 (2012) (0)
- PO-28 Increased thrombin generation (TG) potential of platelets from myeloproliferative neoplasms (2010) (0)
- Organization of a Randomized Clinical Trial for the Prevention of Recurrent Thrombosis in the Antiphospholipid Syndrome: the WAPS Project (Warfarin in Antiphospholipid Syndrome) (1998) (0)
- Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases (2018) (0)
- Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera (2018) (0)
- Epidemiological Study of Salmonella spp. Strains Isolated in Lombardia from 2012-2016 (2017) (0)
- Effects of Antiplatelet Treatment with Aspirin (ASA) on Platelet Reactivity in Patients with Essential Thrombocythemia (2016) (0)
- Abstract citation ID: ckac131.237 Gluten quantification in gluten-free food for celiac people in Lombardy and Emilia Romagna-Italy (2022) (0)
- LA SINDROME DA ANTICORPI ANTIFOSFOLIPIDI (1999) (0)
- Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study (2019) (0)
- [Congenital deficiency of antithrombin III]. (1990) (0)
- enrolled in a prospective observational study Acute leukemia in polycythemia vera: an analysis of 1638 patients (2013) (0)
- Increased platelet thrombus formation under flow conditions in whole blood from polycythaemia vera patients. (2021) (0)
- Management of Patients with Polycythemia Vera (2009) (0)
- Behaviour of Listeria monocytogenes in chunked or sliced seasoned Bresaola della Valtellina IGP. (2009) (0)
- Behaviour of Listeria monocytogenes in delicatessen products: seafood salad. (2010) (0)
- PF671 RATE OF THROMBOSIS IN CONTEMPORARY PATIENTS WITH POLYCYTHEMIA VERA UNDER HYDROXYUREA REMAINS EXCEEDINGLY HIGH. RESULTS OF SYSTEMATIC REVIEW AND METANALYSIS (2019) (0)
- Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms (2018) (0)
- Integrated monitoring of AMR and enterotoxins genes of S. aureus isolated in Lombardy (2022) (0)
- Optimization of Microbiological Recovery from Surfaces for Environmental Monitoring (2016) (0)
- Calreticulin Mutation Does Not Modify the International Prognostic Score for Predicting the Risk of Thrombosis Among 1,150 Patients with Essential Thrombocythemia (2014) (0)
- Erratum: Platelet‐induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera (2011) (0)
- CIABUSCOLO: PROCESS AND PRODUCT STANDARD EVALUATION. PRELIMINARY STUDY (2008) (0)
- Gene mutations in twenty-six families with protein C deficiency (1995) (0)
- CANCER-ASSOCIATED THROMBOTIC DISEASE Myeloproliferative neoplasms and thrombosis (2017) (0)
- P olycythemia vera (2008) (0)
- Listeria monocytogenes behaviour in gastronomy food: octopus and potato salad. (2010) (0)
- international expert panel and primary myelofibrosis: recommendations from an ad hoc diagnostic criteria for polycythemia vera, essential thrombocythemia, Proposals and rationale for revision of the World Health Organization (2009) (0)
- Antithrombin III and Other Natural Inhibitors of Coagulation (1985) (0)
- Acquired thrombophilia: antiphospholipid syndrome and essential thrombocythemia (2002) (0)
- Behaviour of Salmonella Typhimuriumduring production and storage of artisan water buffalo (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Guido Finazzi?
Guido Finazzi is affiliated with the following schools: